Profound Medical (PROF) Q2 2026 Earnings Call Transcript

Profound Medical reported results from its Q2 2026 earnings call on Aug. 6, 2026, led by CEO Arun Swarup Menawat. Revenue was $2.5 million, up 12% year over year, but the company cited a $3.1 million timing shift for shipments completed in July that affected performance. Adjusted revenue reached $5.6 million, up 153% year over year excluding that timing effect. Profound posted a net loss of $9.5 million, or $0.26 per common share, a 39% improvement versus the prior year. Gross margin rose to 78% from 73%. The company ended June 30, 2026 with $38.3 million in cash, announced FY2026 guidance of about $25 million, and said new orders were $7 million, a quarterly record.